Quia Pharma (QUIA) Q2 2025 earnings summary

Executive summary

• Net sales for January–June 2025 were 0 KSEK, with a negative operating result of -6,204 KSEK, reflecting continued lack of commercial revenues and ongoing R&D costs.

• The company’s financial position remains strained, with only 4 KSEK in cash at period end and ongoing efforts to secure long-term financing.

• A rights issue in March 2025 raised 4.4 MSEK before costs, with potential for an additional 4.4 MSEK if all warrants are exercised.

• The planned launch of Omega-3 products via Amazon is delayed, but logistics and marketing partnerships are in place.

• Board and management changes occurred, including new appointments and chair transitions during the period.

Financial highlights

• Operating income for H1 2025 was 51 KSEK, down from 2,360 KSEK in H1 2024, due to absence of one-off invoicing seen last year.

• Operating expenses decreased to -6,255 KSEK from -9,427 KSEK year-over-year, mainly due to lower external and personnel costs.

• Net result after tax was -6,262 KSEK, an improvement from -7,174 KSEK in H1 2024.

• Earnings per share were -0.00 SEK (vs. -0.02 SEK in H1 2024), with 1,965,283,244 shares outstanding at period end.

• Cash flow from operations was -1,494 KSEK, with total cash flow for the period at 2 KSEK.

Outlook and guidance

• The company’s financial situation remains highly strained, with management focused on securing long-term funding and evaluating strategic alternatives.

• Financing for the next 12 months is not secured, and there is significant uncertainty regarding the company’s ability to continue as a going concern.